News
AMGN
263.38
+0.84%
2.19
What's Going On With Amgen Stock On Friday?
Benzinga · 16h ago
Dow up 650 points on gains for shares of Goldman Sachs, NVIDIA Corp.
MarketWatch · 17h ago
Dow Movers: MSFT, AMGN
NASDAQ · 17h ago
BUZZ-U.S. STOCKS ON THE MOVE-Mission Produce, Sirius XM, Carnival Corp
Reuters · 20h ago
Goldman Sachs, Salesforce share gains lead Dow's 300-point jump
MarketWatch · 20h ago
Novo Nordisk Heads For Worst Day In 22 Years As New Obesity Drug Underwhelms: Retail Brushes Off ‘Super Silly’ Drop
Barchart · 20h ago
Why is Novo Nordisk crashing after data for next-gen weight loss drug?
Seeking Alpha · 20h ago
SHARES OF VIKING THERAPEUTICS UP 4.2%, AMGEN UP 1%
Reuters · 21h ago
Novo obesity data positive for Eli Lilly and Amgen, says UBS
TipRanks · 23h ago
BUZZ-Weight-loss drug developers gain after Novo's obesity drug underperforms in study
Reuters · 1d ago
AMGEN SHARES UP 5.3% PREMARKET AFTER NOVO NORDISK'S OBESITY DRUG CAGRISEMA ACHIEVES LOWER WEIGHT LOSS THAN EXPECTED
Reuters · 1d ago
Caterpillar, Epam among additions to Jefferies Franchise Picks list
TipRanks · 1d ago
Can Dow Jones ETF Reverse From the Worst Losing Streak in 50 Years?
NASDAQ · 1d ago
Should You Scoop Up This 'Strong Buy' Biotech Before December 23?
Barchart · 2d ago
BioAge, Novartis team up to discover age-related disease targets
Seeking Alpha · 2d ago
CORRECTED-Amgen hit with $50.3 mln US verdict in cancer drug patent lawsuit
Reuters · 2d ago
Dow’s drop: How blue-chips have fared during index’s peak turned worst-run in decades
Seeking Alpha · 2d ago
Viridian Therapeutics: Veligrotug De-Risked In TED With Hints Of Differentiation
Seeking Alpha · 2d ago
Merck-Hansoh deal for oral GLP-1 hurts obesity drug developers
Seeking Alpha · 2d ago
Dow on a Record Losing Streak: Should You Buy its ETF?
NASDAQ · 2d ago
More
Webull provides a variety of real-time AMGN stock news. You can receive the latest news about Amgen Inc through multiple platforms. This information may help you make smarter investment decisions.
About AMGN
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and improve people's lives. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine), KYPROLIS (carfilzomib), Maridebart cafraglutide, (infliximab-axxq), Evenity, LumaKras, Nplate and XGeva, others.